London
· Delayed Price · Currency is GBP · Price in USD FibroGen Company Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1993 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 486 |
| CEO | Thane Wettig |
Contact Details
Address: 409 Illinois Street San Francisco, Delaware 94158 United States | |
| Phone | 415 978 1200 |
| Website | fibrogen.com |
Stock Details
| Ticker Symbol | 0IL8 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US31572Q8087 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer |
| David DeLucia | Chief Financial Officer |